Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2021-09-11 02:37:03 UTC |
---|
Update Date | 2021-09-26 22:59:23 UTC |
---|
HMDB ID | HMDB0248873 |
---|
Secondary Accession Numbers | None |
---|
Metabolite Identification |
---|
Common Name | Baricitinib |
---|
Description | Baricitinib, also known as olumiant or INCB028050, belongs to the class of organic compounds known as pyrrolo[2,3-d]pyrimidines. These are aromatic heteropolycyclic compounds containing a pyrrolo[2,3-d]pyrimidine ring system, which is an pyrrolopyrimidine isomers having the 3 ring nitrogen atoms at the 1-, 5-, and 7-positions. Based on a literature review very few articles have been published on Baricitinib. This compound has been identified in human blood as reported by (PMID: 31557052 ). Baricitinib is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Baricitinib is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
---|
Structure | CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1 InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20) |
---|
Synonyms | Value | Source |
---|
Olumiant | Kegg | INCB-28050ly3009104 | HMDB | INCB028050 | HMDB | 2-[1-(Ethanesulphonyl)-3-(4-{1h-pyrrolo[2,3-D]pyrimidin-4-yl}-1H-pyrazol-1-yl)azetidin-3-yl]acetonitrile | HMDB |
|
---|
Chemical Formula | C16H17N7O2S |
---|
Average Molecular Weight | 371.42 |
---|
Monoisotopic Molecular Weight | 371.116443989 |
---|
IUPAC Name | 2-[1-(ethanesulfonyl)-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)azetidin-3-yl]acetonitrile |
---|
Traditional Name | 2-[1-(ethanesulfonyl)-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}pyrazol-1-yl)azetidin-3-yl]acetonitrile |
---|
CAS Registry Number | Not Available |
---|
SMILES | CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1 |
---|
InChI Identifier | InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20) |
---|
InChI Key | XUZMWHLSFXCVMG-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as pyrrolo[2,3-d]pyrimidines. These are aromatic heteropolycyclic compounds containing a pyrrolo[2,3-d]pyrimidine ring system, which is an pyrrolopyrimidine isomers having the 3 ring nitrogen atoms at the 1-, 5-, and 7-positions. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Pyrrolopyrimidines |
---|
Sub Class | Pyrrolo[2,3-d]pyrimidines |
---|
Direct Parent | Pyrrolo[2,3-d]pyrimidines |
---|
Alternative Parents | |
---|
Substituents | - Pyrrolo[2,3-d]pyrimidine
- Pyrimidine
- Organic sulfonic acid amide
- Organosulfonic acid amide
- Azole
- Pyrazole
- Pyrrole
- Organic sulfonic acid or derivatives
- Organosulfonic acid or derivatives
- Sulfonyl
- Heteroaromatic compound
- Azetidine
- Carbonitrile
- Nitrile
- Azacycle
- Organic oxygen compound
- Organic nitrogen compound
- Organopnictogen compound
- Organonitrogen compound
- Organosulfur compound
- Hydrocarbon derivative
- Organic oxide
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Baricitinib,1TMS,isomer #1 | CCS(=O)(=O)N1CC(CC#N)(N2C=C(C3=NC=NC4=C3C=CN4[Si](C)(C)C)C=N2)C1 | 3462.8 | Semi standard non polar | 33892256 | Baricitinib,1TMS,isomer #1 | CCS(=O)(=O)N1CC(CC#N)(N2C=C(C3=NC=NC4=C3C=CN4[Si](C)(C)C)C=N2)C1 | 3506.3 | Standard non polar | 33892256 | Baricitinib,1TMS,isomer #1 | CCS(=O)(=O)N1CC(CC#N)(N2C=C(C3=NC=NC4=C3C=CN4[Si](C)(C)C)C=N2)C1 | 5134.0 | Standard polar | 33892256 | Baricitinib,1TBDMS,isomer #1 | CCS(=O)(=O)N1CC(CC#N)(N2C=C(C3=NC=NC4=C3C=CN4[Si](C)(C)C(C)(C)C)C=N2)C1 | 3645.3 | Semi standard non polar | 33892256 | Baricitinib,1TBDMS,isomer #1 | CCS(=O)(=O)N1CC(CC#N)(N2C=C(C3=NC=NC4=C3C=CN4[Si](C)(C)C(C)(C)C)C=N2)C1 | 3755.7 | Standard non polar | 33892256 | Baricitinib,1TBDMS,isomer #1 | CCS(=O)(=O)N1CC(CC#N)(N2C=C(C3=NC=NC4=C3C=CN4[Si](C)(C)C(C)(C)C)C=N2)C1 | 5079.6 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Baricitinib GC-MS (Non-derivatized) - 70eV, Positive | splash10-004i-9362000000-0e97820f52a9991d1419 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Baricitinib GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Baricitinib 10V, Positive-QTOF | splash10-00di-1219000000-6fa31e49e108be908483 | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Baricitinib 20V, Positive-QTOF | splash10-0a4l-3964000000-754d812e94a1407aa203 | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Baricitinib 40V, Positive-QTOF | splash10-0002-9720000000-a83fecb42ab025ba86fa | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Baricitinib 10V, Negative-QTOF | splash10-0300-1294000000-afb84db266bf6933b5c0 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Baricitinib 20V, Negative-QTOF | splash10-052f-3719000000-97cbc394ce7d41ae5da9 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Baricitinib 40V, Negative-QTOF | splash10-01ox-9201000000-2f1faf038cc61eced687 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Baricitinib 10V, Positive-QTOF | splash10-00di-0009000000-940be979c20cb493c494 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Baricitinib 20V, Positive-QTOF | splash10-00di-0149000000-0b93b8bf2be133cc1167 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Baricitinib 40V, Positive-QTOF | splash10-0f79-2290000000-6d5cf4bbb18553e6f58c | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Baricitinib 10V, Negative-QTOF | splash10-00di-0009000000-4b69070afb65176af304 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Baricitinib 20V, Negative-QTOF | splash10-00b9-1295000000-e3fe9c9696ca39d3f781 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Baricitinib 40V, Negative-QTOF | splash10-03e9-9720000000-bf065631db0fec4ae515 | 2021-10-12 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum |
|
---|